BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26973396)

  • 21. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.
    Kennedy AS; McNeillie P; Dezarn WA; Nutting C; Sangro B; Wertman D; Garafalo M; Liu D; Coldwell D; Savin M; Jakobs T; Rose S; Warner R; Carter D; Sapareto S; Nag S; Gulec S; Calkins A; Gates VL; Salem R
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1494-500. PubMed ID: 19157721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction.
    Gaba RC; Riaz A; Lewandowski RJ; Ibrahim SM; Ryu RK; Sato KT; Omary RA; Salem R
    J Vasc Interv Radiol; 2010 Aug; 21(8):1213-8. PubMed ID: 20598575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
    Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
    Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary?
    McCann JW; Larkin AM; Martino LJ; Eschelman DJ; Gonsalves CF; Brown DB
    J Vasc Interv Radiol; 2012 May; 23(5):661-7. PubMed ID: 22440592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microvascular injury in persistent gastric ulcers after yttrium-90 microsphere radioembolization for liver malignancies.
    Sun B; Lapetino SR; Diffalha SA; Yong S; Gaba RC; Bui JT; Koppe S; Garzon S; Guzman G
    Hum Pathol; 2016 Apr; 50():11-4. PubMed ID: 26997433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastric radiation enteritis after intra-arterial yttrium-90 microsphere therapy for early stage hepatocellular carcinoma.
    Aloia TA; Barakat O; Connelly J; Haykal N; Michel D; Gaber AO; Ghobrial RM
    Exp Clin Transplant; 2009 Sep; 7(3):141-4. PubMed ID: 19715522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.
    Wong CY; Savin M; Sherpa KM; Qing F; Campbell J; Gates VL; Lewandowski RJ; Cheng V; Thie J; Fink-Bennett D; Nagle C; Salem R
    Cancer Biother Radiopharm; 2006 Aug; 21(4):305-13. PubMed ID: 16999596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.
    Lam MG; Abdelmaksoud MH; Chang DT; Eclov NC; Chung MP; Koong AC; Louie JD; Sze DY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):323-9. PubMed ID: 23849697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
    Young JY; Rhee TK; Atassi B; Gates VL; Kulik L; Mulcahy MF; Larson AC; Ryu RK; Sato KT; Lewandowski RJ; Omary RA; Salem R
    J Vasc Interv Radiol; 2007 Nov; 18(11):1375-82. PubMed ID: 18003987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes.
    Piana PM; Bar V; Doyle L; Anne R; Sato T; Eschelman DJ; McCann JW; Gonsalves CF; Brown DB
    HPB (Oxford); 2014 Apr; 16(4):336-41. PubMed ID: 23782387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.
    Smits ML; van den Hoven AF; Rosenbaum CE; Zonnenberg BA; Lam MG; Nijsen JF; Koopman M; van den Bosch MA
    PLoS One; 2013; 8(7):e69448. PubMed ID: 23894481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
    Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.